Investors focused on the Medical space have likely heard of Vertex Pharmaceuticals (VRTX - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Vertex Pharmaceuticals is one of 931 individual stocks in the Medical sector. Collectively, these companies sit at #13 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. VRTX is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for VRTX's full-year earnings has moved 16.05% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that VRTX has returned about 0.71% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 0.21% on average. This shows that Vertex Pharmaceuticals is outperforming its peers so far this year.
Looking more specifically, VRTX belongs to the Medical - Biomedical and Genetics industry, a group that includes 414 individual stocks and currently sits at #177 in the Zacks Industry Rank. On average, this group has lost an average of 1.08% so far this year, meaning that VRTX is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track VRTX. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of Vertex Pharmaceuticals (VRTX - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Vertex Pharmaceuticals is one of 931 individual stocks in the Medical sector. Collectively, these companies sit at #13 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. VRTX is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for VRTX's full-year earnings has moved 16.05% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that VRTX has returned about 0.71% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 0.21% on average. This shows that Vertex Pharmaceuticals is outperforming its peers so far this year.
Looking more specifically, VRTX belongs to the Medical - Biomedical and Genetics industry, a group that includes 414 individual stocks and currently sits at #177 in the Zacks Industry Rank. On average, this group has lost an average of 1.08% so far this year, meaning that VRTX is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track VRTX. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on VRTX - FREE